Skip to Content
Merck
  • Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.

Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.

European journal of medicinal chemistry (2011-03-25)
Liang Ma, Shilin Li, Hao Zheng, Jinying Chen, Lin Lin, Xia Ye, Zhizhi Chen, Qinyuan Xu, Tao Chen, Jincheng Yang, Neng Qiu, Guangcheng Wang, Aihua Peng, Yi Ding, Yuquan Wei, Lijuan Chen
ABSTRACT

Forty-four barbituric acid or thiobarbituric acid derivatives were synthesized and evaluated for their effects on adipogenesis of 3T3-L1 adipocytes by measuring the expression of adiponectin in vitro. Four compounds (3a, 3o, 3s, 4t) were found to increase the expression of adiponectin and lower the leptin level in 3T3-L1 adipocytes at respective concentration of 10 μM. Among them, 3s showed the most efficacious. Oral administration of 3s effectively reduced body weight, liver weight, and visceral fat and regulated serum levels of biochemical markers in the high-fat/diet-induced Wistar rats. Histopathological evaluation of liver sections by Oil Red O and H&E staining confirmed 3s as a potent, orally active molecule for reducing fat deposition against non-alcoholic fatty liver disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium barbiturate, ≥97.0% (T)
Sigma-Aldrich
Barbituric acid, ReagentPlus®, 99%
Supelco
Barbituric acid, for spectrophotometric det. of cyanide, ≥99.5%